Second, tumor burden as a source of VEGF-A (target of bevacizumab) is irrelevant for bevacizumab PK because bevacizumab molar concentration is thousands of times higher than that of VEGF-A [10], and there has been no evidence of target-mediated drug disposition (TMDD) for bevacizumab [10]. Here, VEGFA is linked to neoplasm.